M. Omori

发表

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

D. V. Von Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012, Molecular Cancer Therapeutics.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

R. Hannan, M. Bywater, E. Sanij, 2011, Cancer research.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2010, Cancer research.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

Therapeutics , Targets , and Chemical Biology CX-4945 , an Orally Bioavailable Selective Inhibitor of Protein Kinase CK 2 , Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Brien, Adam Siddiqui-Jain, J. Bliesath, 2010 .

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Preclinical Development CK 2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Ef fi cacy : Mechanistic Rationale for Drug Combination Therapy

D. V. Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012 .

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, Cancer letters.

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Biochemical and biophysical research communications.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

Expression of α‐fetoprotein and stem cell factor/c‐kit system in bile duct ligated young rats

S. Thorgeirsson, M. Omori, R. Evarts, 1997 .

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.